Results 171 to 180 of about 7,776 (285)

The Impact of Nusinersen and Risdiplam on Motor Function for Spinal Muscular Atrophy Type 2 and 3: A Meta-Analysis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Spinal muscular atrophy (SMA) is a prevalent paediatric neuromuscular disorder characterised by muscle weakness and atrophy resulting from degeneration of spinal cord anterior horn α motor neurons.
Bo Chen, Yuanlin Gong, Tengteng Zhou
semanticscholar   +1 more source

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy [PDF]

, 2022
Rotem Orbach, Liora Sagi, Efraim Sadot, Itay Tokatly Latzer, Anna Shtamler, Tehila Zisberg, Aviva Fattal‐Valevski   +6 more
openalex   +1 more source

Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

Cellular and molecular life sciences : CMLS
Aim The availability of disease-modifying therapies and newborn screening programs for spinal muscular atrophy (SMA) has generated an urgent need for reliable prognostic biomarkers to classify patients according to disease severity.
C. Panicucci, Eray Şahin, Martina Bartolucci, S. Casalini, N. Brolatti, M. Pedemonte, S. Baratto, Sara Pintus, Elisa Principi, Adele D'Amico, Marika Pane, Marina Sframeli, S. Messina, E. Albamonte, V. Sansone, Eugenio Mercuri, E. Bertini, U. Sezerman, Andrea Petretto, Claudio Bruno   +19 more
semanticscholar   +1 more source

POSB339 Real-World Adherence of Nusinersen for the Treatment of Spinal Muscular Atrophy (SMA) Using US Large Administrative Claims Dataset [PDF]

, 2022
Nicole B. Johnson, Qiang Hou, AD Paradis, Crystal M. Proud, Bora Youn   +4 more
openalex   +1 more source

Performance fatigability in adults with spinal muscular atrophy treated long‐term with nusinersen

Muscle and Nerve
Persons with spinal muscular atrophy (pwSMA) report progressive muscle weakness but also reduced endurance when performing repetitive tasks in daily life, referred to as “performance fatigability” (PF).
B. Stolte, Svenja Neuhoff, J. Lipka, M. Schlag, O. von Velsen, T. Kruse, C. Deuschl, C. Kleinschnitz, T. Hagenacker   +8 more
semanticscholar   +1 more source

P.166 Subcutaneous intrathecal catheter and port implants for administration of Nusinersen in patients with Spinal Muscular Atrophy [PDF]

, 2022
A Bokeris, D Mcneely, J Sheriko
openalex   +1 more source

Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy [PDF]

, 2023
Olivia Schreiber‐Katz, Hannah Siegler, Gary Wieselmann, Mareike Kumpe, Gresa Ranxha, Susanne Petri, Alma Osmanovic   +6 more
openalex   +1 more source

Computed tomography-guided transforaminal lumbar puncture using local anesthesia and a straight 22-gauge spinal needle for intrathecal nusinersen in adults: Findings in 77 procedures

, 2021
Mougnyan Cox, Kofi‐Buaku Atsina, Preethi Ramchand, Jonathan Ji, Neda I. Sedora-Román, Bryan Pukenas   +5 more
openalex   +2 more sources

An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy [PDF]

, 2023
Bogdan Bjelica, Camilla Wohnrade, Alma Osmanovic, Olivia Schreiber‐Katz, Susanne Petri   +4 more
openalex   +1 more source

Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers

, 2020
Er Chen, Stacy Dixon, Rupali Naik, Josh Noone, J.D. Buchenberger, Sarah Whitmire, Rosalina Mills, W. David Arnold   +7 more
openalex   +1 more source